Creating Small Molecule Drugs for Viral Infections and Liver Diseases

Learn More
  • News

    Enanta Announces New Data on EDP-938, a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV), at

  • Research

    At Enanta, our research is focused on multiple therapeutic areas where there in a high unmet need.

    Learn More.

  • Careers

    Join the Enanta Team

    Learn More.

Enanta’s diversified portfolio is focused primarily on unmet medical needs such as non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV)